Soluble TREM2 is associated with clinical progression of Alzheimer’s disease.

Functional loss of the microglial receptor TREM2 has been linked to the development of Alzheimer’s disease (AD) (1). A recent study by Ewers et al. reported that increased soluble TREM2 (sTREM2) measured in cerebrospinal fluid (CSF) was associated with lower rates of cognitive and clinical decline and progression in people with AD or mild cognitive impairment (MCI) (2). Importantly, an increased ratio of CSF sTREM2 to p-tau₁₈₁ concentrations was useful as a predictor of slowed conversion of normal to compromised cognition or from MCI to AD in individuals with CSF Aβ_1-42 and CSF p-tau₁₈₁ expression. This work presents a very exciting perspective on the relationship between AD and the innate immune system, as well as encouraging further research into TREM2 signaling as a potential therapeutic approach for AD.

GeneTex is proud to offer an outstanding selection of antibody reagents to facilitate your research of neurodegenerative diseases. Featured antibodies against unique markers are shown below. Please click here to visit our website for details.